top of page
Search

RootPath raises $50m

  • Writer: Volcanics Venture
    Volcanics Venture
  • Sep 26, 2021
  • 1 min read

RootPath Genomics, a preclinical-stage biotech firm that develops personalised immunotherapy and cell therapy for solid tumours, has raised $50 million in a Series B round.


RootPath, which has its office in the US, plans to use the financing to fund the development and commercialisation of its product pipeline, including the construction of GMP facilities in China for investigator initiated trials (IITs) and Phase I clinical trials.

 
 
 

Comments


bottom of page